Are You Looking for a Top Momentum Pick? Why Bioventus (BVS) is a Great Choice
Does Bioventus (BVS) have what it takes to be a top stock pick for momentum investors? Let's find out.
BVS - Bioventus Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$14.00
DETAILS
HIGH:
$15.00
LOW:
$13.00
MEDIAN:
$14.00
CONSENSUS:
$14.00
UPSIDE:
17.85%
Stock News
Wall Street Analysts Predict a 28.81% Upside in Bioventus (BVS): Here's What You Should Know
The mean of analysts' price targets for Bioventus (BVS) points to a 28.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Bioventus: I See A Better Business Trading At A Fair Price (Upgrade)
Bioventus Inc. develops medical devices and biologics for orthopedic recovery and pain relief. I previously rated it a 'Hold' due to debt, competition, weak cash flow, and valuation concerns despite strong Q2 2024 growth. BVS has recently outperformed the S&P 500 and medtech ETFs, with a breakout driven by favorable regulatory developments.
Bioventus (BVS) Soars 12.4%: Is Further Upside Left in the Stock?
Bioventus (BVS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Did Bioventus Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
3 Top Breakout Stocks to Snap Up for Big Upside in July 2026
FA, BVS and OOMA emerged as July breakout stock picks after meeting momentum and price-based screens designed to spot potential upside.
Should Value Investors Buy Bioventus (BVS) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Investors Undervaluing Bioventus (BVS) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Bioventus Highlights PNS, PRP Growth as Cash Flow Improves and Debt Falls
Bioventus NASDAQ: BVS executives outlined the company's portfolio strategy, growth priorities and capital allocation plans during a Goldman Sachs event hosted by Jenny Rabinowitz, an analyst covering U.S. medtech and healthcare IT.
Bioventus Inc. (BVS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Bioventus Inc. (BVS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
After Plunging 22% in 4 Weeks, Here's Why the Trend Might Reverse for Bioventus (BVS)
The heavy selling pressure might have exhausted for Bioventus (BVS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Bioventus to Present at the Goldman Sachs 47TH Annual Global Healthcare Conference
DURHAM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, Bioventus Senior Vice-President and Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on Monday, June 8, 2026, at 4:00 p.m. ET.
Bioventus to Present at the Goldman Sachs 47TH Annual Global Healthcare Conference
DURHAM, N. C. , June 02, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, Bioventus Senior Vice-President and Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on Monday, June 8, 2026, at 4:00 p.
Bioventus (BVS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Bioventus (BVS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Is Bioventus (BVS) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Medical Stocks Lagging Bioventus (BVS) This Year?
Here is how Bioventus (BVS) and Allarity Therapeutics, Inc. (ALLR) have performed compared to their sector so far this year.
Consumer Sentiment Just Crashed Below the Recession Threshold. These 3 Defensive Stocks Under $25 Are Built for What Comes Next
Consumer confidence is breaking down in a way investors have not seen in years. The University of Michigan Consumer Sentiment Index landed at 53.3 in March 2026, sitting below the 60 recessionary threshold, and the latest Surveys of Consumers reading dropped further to 49.8 in April 2026, a 6.6% month-over-month decline matching the trough from June 2022.
Wall Street Analysts See a 38.97% Upside in Bioventus (BVS): Can the Stock Really Move This High?
The consensus price target hints at a 39% upside potential for Bioventus (BVS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Bioventus Inc. (BVS) Q1 2026 Earnings Call Transcript
Bioventus Inc. (BVS) Q1 2026 Earnings Call Transcript
Bioventus (BVS) Surpasses Q1 Earnings and Revenue Estimates
Bioventus (BVS) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.08 per share a year ago.
Price Targets
Canaccord Reiterates Buy Rating on Bioventus Inc (BVS)
$15.00
(was $8.60)
Caitlin Cronin
·
Canaccord Genuity
Bioventus initiated with an Outperform at Barrington
$13.00
(was $8.51)
Barrington
Bioventus price target lowered to $15 from $17 at Craig-Hallum
$15.00
(was $6.20)
Chase Knickerbocker
·
Craig-Hallum
Canaccord Genuity Reiterates Buy Rating on Bioventus Inc (BVS)
$12.00
(was $11.79)
Caitlin Cronin
·
Canaccord Genuity
Bioventus price target raised to $12 from $9 at Craig-Hallum
$12.00
(was $8.25)
Chase Knickerbocker
·
Craig-Hallum
Bioventus Inc (BVS) PT Raised to $8 at Canaccord Genuity
$8.00
(was $5.12)
William Plovanic
·
Canaccord Genuity
Bioventus Inc (BVS) PT Raised to $9 at Craig-Hallum
$9.00
(was $5.29)
Alex Nowak
·
Craig-Hallum
Goldman Sachs Maintains Neutral on Bioventus, Lowers Price Target to $2.5
$2.50
(was $1.91)
Goldman Sachs